证券之星消息，截至2025年8月26日收盘，天臣医疗(688013)报收于50.0元，上涨10.5%，换手率5.6%， 成交量4.55万手，成交额2.19亿元。 8月26日的资金流向数据方面，主力资金净流入1811.8万元，占总成交额8.29%，游资资金净流出145.53 万元，占总成交额0.67%，散户资金净流出1666.27万元，占总成交额7.62%。 近5日资金流向一览见下表： | 日期 | 涨跌幅 | 融资余额(元) | 融资净买入(元) | 融券余重(股) | 融券净卖出(股) | 融资融券余额(元) | | --- | --- | --- | --- | --- | --- | --- | | 2025-08-26 | 10.50% | 1.21亿 | 712.46万 | 0.0 | 0.0 | 1.21亿 | | 2025-08-25 | 6.07% | 1.14亿 | 470.77万 | 0.0 | 0.0 | 1.14亿 | | 2025-08-22 | 3.42% | 1.09亿 | 255.25万 | 0.0 | 0.0 | 1.09 乙 | | 2025-08-21 | 3.44% | ...

证券之星消息，截至2025年8月6日收盘，天臣医疗(688013)报收于37.88元，下跌4.51%，换手率7.1%， 成交量5.76万手，成交额2.15亿元。 近5日融资融券数据一览见下表： | 日期 | 涨跌幅 | 融资余额(元) | 融资净买入(元) | 融券会量(股) | 融券净卖出(股) | 融资融券余额(元) | | --- | --- | --- | --- | --- | --- | --- | | 2025-08-06 | -4.51% | 1.02亿 | 1297.25万 | 0.0 | 0.0 | 1.02亿 | | 2025-08-05 | -0.78% | 8884.32万 | 937.45万 | 0.0 | 0.0 | 8884.32万 | | 2025-08-04 | 3.28% | 7946.87万 | -169.97万 | 0.0 | 0.0 | 7946.87万 | | 2025-08-01 | 0.73% | 8116.84万 | -156.76万 | 0.0 | 0.0 | 8116.84万 | | 2025-07-31 | 0.03% | 8273.61万 | 111 ...

Core Viewpoint - Tianchen Medical (688013) has shown a positive stock performance with a closing price of 30.74 yuan, up 2.5% as of July 7, 2025, indicating a potential upward trend in investor sentiment [1] Financial Performance - The company reported a main revenue of 65.84 million yuan for Q1 2025, representing a year-on-year increase of 9.34% - The net profit attributable to shareholders was 13.19 million yuan, up 16.16% year-on-year - The net profit after deducting non-recurring gains and losses was 11.07 million yuan, with a slight increase of 0.5% year-on-year - The company's debt ratio stands at 13.25%, with investment income of 1.32 million yuan and financial expenses of -2.77 million yuan - The gross profit margin is reported at 58.46% [4] Market Position - Tianchen Medical's total market capitalization is 2.495 billion yuan, significantly lower than the industry average of 10.66 billion yuan, ranking 110 out of 122 in the medical device industry - The company's net assets are 572 million yuan, compared to the industry average of 3.919 billion yuan, ranking 114 out of 122 - The net profit of 13.19 million yuan ranks 77 out of 122 in the industry, while the price-to-earnings ratio (P/E) is 47.3, lower than the industry average of 57.66, ranking 58 out of 122 - The price-to-book ratio (P/B) is 4.69, higher than the industry average of 3.47, ranking 97 out of 122 - The company's net profit margin is 20.03%, significantly higher than the industry average of 10.86%, ranking 35 out of 122 - Return on equity (ROE) is reported at 2.38%, compared to the industry average of 1.01%, ranking 33 out of 122 [4] Capital Flow - On July 7, 2025, the net inflow of main funds was 104,200 yuan, accounting for 0.17% of the total transaction amount, while retail investors saw a net inflow of 1.68 million yuan, representing 2.76% of the total transaction amount - Over the past five days, the stock has experienced fluctuations in capital flow, with notable net outflows from speculative funds [1][2]